AnaptysBio Ownership | Who Owns AnaptysBio?
AnaptysBio Ownership Summary
AnaptysBio is owned by 116.33% institutional investors, 1.74% insiders. Ecor1 capital is the largest institutional shareholder, holding 27.49% of ANAB shares. SPDR® S&P Biotech ETF is the top mutual fund, with 2.65% of its assets in AnaptysBio shares.
ANAB Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | AnaptysBio | 116.33% | 1.74% | -18.06% |
Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
Industry | Biotech Stocks | 109.70% | 8.77% | -18.47% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Ecor1 capital | 7.52M | 27.49% | $188.48M |
Fmr | 2.87M | 10.49% | $71.94M |
Frazier life sciences management | 2.17M | 7.92% | $54.27M |
Blackrock | 1.77M | 6.47% | $44.35M |
Vanguard group | 1.42M | 5.21% | $35.70M |
Tang capital management | 1.33M | 4.87% | $33.35M |
Boxer capital | 1.30M | 4.75% | $32.58M |
State street | 966.85K | 3.53% | $24.23M |
Palo alto investors lp | 803.64K | 2.94% | $20.14M |
First light asset management | 779.16K | 2.85% | $19.53M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Ecor1 capital | 7.52M | 5.77% | $188.48M |
Tang capital management | 1.33M | 3.40% | $33.35M |
Frazier life sciences management | 2.17M | 2.54% | $54.27M |
Palo alto investors lp | 803.64K | 2.33% | $20.14M |
5am venture management | 357.73K | 2.01% | $8.96M |
Boxer capital | 1.30M | 1.72% | $32.58M |
First light asset management | 779.16K | 1.71% | $19.53M |
Mangrove partners | 689.52K | 1.33% | $17.28M |
Parkman healthcare partners | 256.31K | 0.86% | $6.42M |
Eventide asset management | 568.32K | 0.24% | $14.24M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Fmr | 2.87M | 0.00% | 2.73M |
Frazier life sciences management | 2.17M | 2.54% | 1.27M |
Parkman healthcare partners | 256.31K | 0.86% | 256.31K |
Schonfeld strategic advisors | 171.59K | 0.03% | 171.59K |
Eventide asset management | 568.32K | 0.24% | 141.32K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Point72 asset management | 17.90K | 0.00% | -846.20K |
Morgan stanley | 91.77K | 0.00% | -544.35K |
Deep track capital, lp | - | - | -529.45K |
Camber capital management lp | - | - | -500.00K |
Blackstone | - | - | -328.72K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Parkman healthcare partners | 256.31K | 0.86% | 256.31K | $6.42M |
Schonfeld strategic advisors | 171.59K | 0.03% | 171.59K | $4.30M |
Cubist systematic strategies | 54.27K | 0.01% | 54.27K | $1.36M |
Jump financial | 35.70K | 0.02% | 35.70K | $894.64K |
Alpha dna investment management | 15.92K | 0.15% | 15.92K | $398.95K |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -4.00 |
Northwestern mutual wealth management | -7.00 |
Westend capital management | -29.00 |
Fortitude family office | -31.00 |
Avion wealth | -36.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 173 | 26.28% | 33,610,268 | 12.80% | 116 | 0.98% | 102 | 52.24% | 32 | -28.89% |
Jun 30, 2024 | 137 | -1.44% | 29,796,164 | 1.98% | 108 | 0.92% | 67 | 3.08% | 45 | 12.50% |
Mar 31, 2024 | 139 | 12.10% | 29,216,786 | -3.19% | 109 | 0.87% | 65 | 41.30% | 40 | -9.09% |
Dec 31, 2023 | 124 | 1.64% | 30,178,965 | -0.47% | 112 | 0.86% | 46 | -4.17% | 44 | 15.79% |
Sep 30, 2023 | 122 | -0.81% | 30,320,577 | 0.30% | 114 | 0.89% | 48 | -7.69% | 38 | 8.57% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
SPDR® S&P Biotech ETF | 807.47K | 2.65% | -9.44K |
Vanguard Total Stock Mkt Idx Inv | 668.95K | 2.20% | - |
Fidelity Small Cap Growth | 625.15K | 2.05% | - |
iShares Russell 2000 ETF | 577.26K | 1.90% | -2.23K |
T. Rowe Price New Horizons | 552.81K | 1.82% | -138.30K |
US Small-Cap Growth II Equity Comp | 552.81K | 1.82% | 230.69K |
FIAM Small Cap Core Composite | 547.80K | 1.80% | 96.95K |
FIAM Small Cap Core CIT Cl B | 470.60K | 1.55% | -77.20K |
Fidelity Advisor Biotechnology I | 423.10K | 1.39% | - |
T. Rowe Price Health Sciences | 348.01K | 1.14% | -19.42K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Dec 30, 2024 | EcoR1 Capital, LLC | Buy | $842.06K | |
Dec 31, 2024 | EcoR1 Capital, LLC | Buy | $171.51K | |
Jan 02, 2025 | EcoR1 Capital, LLC | Buy | $86.07K | |
Nov 29, 2024 | RENTON HOLLINGS | - | Sell | $250.00K |
Sep 23, 2024 | Lizzul Paul F. | Chief Medical Officer | Sell | $58.01K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q4 | 2 | 1 |
2024 Q3 | 1 | 11 |
2024 Q2 | - | 3 |
2024 Q1 | - | 8 |
2023 Q4 | - | 1 |
ANAB Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools